Ontology highlight
ABSTRACT:
SUBMITTER: Khalse M
PROVIDER: S-EPMC6166543 | biostudies-other | 2018 Sep-Oct
REPOSITORIES: biostudies-other
Indian journal of endocrinology and metabolism 20180901 5
The U.S. Food and Drug Administration issued a guidance for pharmaceutical industry defining preapproval and postapproval requirements for the demonstration of cardiovascular (CV) safety for all new medications developed for glycemic management in type 2 diabetes. However, results published from the studies of dipeptidyl peptidase-4 (DPP-4) inhibitors are conflicting with regard to different CV endpoints. Upcoming CV outcome studies perhaps will be able to provide additional insights related to ...[more]